Lucinda Puebla-Clark

Lucinda Puebla-Clark

Auto-generated profile, based on publicly available information

Lucinda Puebla-Clark

Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in iScience
Verified
Journal Article
Open access
VCVictor H. Carpio
Victor H. Carpio
FAFlorentin Aussenac
Florentin Aussenac
LPLucinda Puebla-Clark
Lucinda Puebla-Clark
KWKyle D. Wilson
Kyle D. Wilson
AVAlejandro V. Villarino
Alejandro V. Villarino
RSRobin Stephens
Robin Stephens
Hybrid Th1/Tfh cells (IFN-γ+IL-21+CXCR5+) predominate in response to several persistent infections. In Plasmodium chabaudi infection, IFN-γ+ T cells control parasitemia, whereas antibody and IL-21+Bcl6+ T cells effect final clearance, suggesting an evolutionary driver for the hybrid population. We found that CD4-intrinsic Bcl6, Blimp-1, and STAT3 coordinately regulate expression of the Th1 master regulator T-bet, supporting plasticity of CD4 T cells. Bcl6 and Blimp-1 regulate CXCR5 levels, and T-bet, IL-27Rα, and STAT3 modulate cytokines in hybrid Th1/Tfh cells. Infected mice with STAT3 knockout (KO) T cells produced less antibody and more Th1-like IFN-γ+IL-21−CXCR5lo effector and memory cells and were protected from re-infection. Conversely, T-bet KO mice had reduced Th1-bias upon re-infection and prolonged secondary parasitemia. Therefore, each feature of the CD4 T cell population phenotype is uniquely regulated in this persistent infection, and the cytokine profile of memory T cells can be modified to enhance the effectiveness of the secondary response.

1 April 2018 in Molecular Immunology
Verified
Journal Article
Closed access
HPHéctor Parra-Sánchez
Héctor Parra-Sánchez
LPLucinda Puebla-Clark
Lucinda Puebla-Clark
MRMónica Reséndiz
Mónica Reséndiz
OVOlivia Valenzuela-Antelo
Olivia Valenzuela-Antelo
Jesús HernándezJesús Hernández
Jesús Hernández

1 March 2019 in Virology
Verified
Journal Article
Closed access
LPLucinda Puebla-Clark
Lucinda Puebla-Clark
HPHéctor Parra-Sánchez
Héctor Parra-Sánchez
MRMónica Reséndiz
Mónica Reséndiz
OVOlivia Valenzuela-Antelo
Olivia Valenzuela-Antelo
Jesús HernándezJesús Hernández
Jesús Hernández

17 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMaria Gonzalez-Orozco
Maria Gonzalez-Orozco
HTHsiang-Chi Tseng
Hsiang-Chi Tseng
AHAdam Hage
Adam Hage
HXHongjie Xia
Hongjie Xia
PBPadmanava Behera
Padmanava Behera
RRRicardo Rajsbaum
Ricardo Rajsbaum
SARS-CoV-2 is a highly transmissible virus that causes COVID-19 disease. Mechanisms of viral pathogenesis include excessive inflammation and viral-induced cell death, resulting in tissue damage. We identified the host E3-ubiquitin ligase TRIM7 as an inhibitor of apoptosis and SARS-CoV-2 replication via ubiquitination of the viral membrane (M) protein. Trim7 -/- mice exhibited increased pathology and virus titers associated with epithelial apoptosis and dysregulated immune responses. Mechanistically, TRIM7 ubiquitinates M on K14, which protects cells from cell death. Longitudinal SARS-CoV-2 sequence analysis from infected patients revealed that mutations on M-K14 appeared in circulating variants during the pandemic. The relevance of these mutations was tested in a mouse model. A recombinant M- K14/K15R virus showed reduced viral replication, consistent with the role of K15 in virus assembly, and increased levels of apoptosis associated with the loss of ubiquitination on K14. TRIM7 antiviral activity requires caspase-6 inhibition, linking apoptosis with viral replication and pathology.

27 July 2018 in Nova Scientia
Verified
Journal Article
Open access
PDF file
MMMaricela Montalvo-Corral
Maricela Montalvo-Corral
LCLucinda Puebla Clark
Lucinda Puebla Clark
GRGuadalupe López Robles
Guadalupe López Robles
IDItzel Reyes Duarte
Itzel Reyes Duarte
GCGuillermo López Cervantes
Guillermo López Cervantes
Silvia Yolanda Moya-CamarenaSilvia Yolanda Moya-Camarena
Silvia Yolanda Moya-Camarena
Introduction: Giardia lamblia, a protozoan intestinal parasite is able to evade or suppress defense mechanisms, such as innate response. Antigen presenting cells (APC) like dendritic cells may orchestrate an immune response and support a more effective adaptive defense. Conjugated linoleic acid (CLA), a dietary lipid, has shown biological activity on APC. The aim was to evaluate the effect of CLA in intestinal innate response measuring the frequency of mucosal APC populations in Giardia lamblia murine infection.Method: The giardiasis infection model was established in C3H/HeN mice (n=32), and parasite load was followed at 0, 2, 6 and 8 days post infection (dpi). APC obtained from small intestine by enzymatic digestion were assessed by flow cytometry. Oral supplementation with CLA (50:50 of cis-9, trans-11-CLA and trans-10, cis-12-CLA isomers) and placebo control begun three days before infection and continued during first week post infection.Results: Infection kinetics showed a peak of trophozoites at 6 dpi in acute phase. Parasite load was lower in CLA group in comparison with control infected group (p<0.05). Conjugated linoleic acid stimulates innate immune response, percentage of intestinal CD11chiMHC-IIhi increases after 2 dpi, meanwhile CD11chiMHC-IIhiCD103+ APC was higher after three days of CLA supplementation than control (p<0.05). Also, the CD11c+ F4/80+ population shown a percentage increases after 6 and 8 dpi by the effect of treatment and time of infection (p<0.05).Conclusion: In conclusion CLA increased percentages of small intestine APC phenotypes CD11chiMHCIIhi, CD11chiMHCIIhiCD103+ and CD11c+ F4/80+, and reduced G. lamblia parasitic load. Further studies are needed to elucidate potential mechanisms involved in CLA immunomodulatory effect and its contribution in adaptive immune response.

14 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSolomon Taye Sima
Solomon Taye Sima
LPLucinda Puebla-Clark
Lucinda Puebla-Clark
MGMaria Gonzalez-Orozco
Maria Gonzalez-Orozco
MEMark Joseph Endrino
Mark Joseph Endrino
TSThomas R. Shelite
Thomas R. Shelite
RSRobin Stephens
Robin Stephens
The pathology of severe COVID-19 is due to a hyperinflammatory immune response persisting after viral clearance. To understand how the immune response to SARS-CoV-2 is regulated to avoid severe COVID-19, we tested relevant immunoregulatory cytokines. TGF-β, IL-10 and IL-4 were neutralized upon infection with mouse-adapted SARS-CoV-2 (CMA3p20), a model of mild disease; and lung inflammation was quantified by histology and flow cytometry at early and late time points. Mild weight loss, and lung inflammation including consolidation and alveolar thickening were evident 3 days post-infection (dpi) and inflammation persisted to 7 dpi. Coinciding with early monocytic infiltrates, CCL2 and granulocyte-colony stimulating factor (G-CSF) were transiently produced 3 dpi, while IL-12 and CCL5 persisted to 7 dpi, modeling viral and inflammatory phases of disease. Neutralization of TGF-β, but not IL-10 or IL-4, significantly increased lung inflammatory monocytes and elevated serum but not lung IL-6. Neutralization of IL-4 prolonged weight loss and increased early perivascular infiltration without changing viral titer. Anti-IL-4 reduced expression of Arg1 , a gene associated with alternative activation of macrophages. Neutralizing TGF-β and IL-4 had differential effects on pathology after virus control. Lung perivascular infiltration was reduced 7 dpi by neutralization of IL-4 or TGF-β, and peri-airway inflammation was affected by anti-TGF-β, while alveolar infiltrates were not affected by either. Anti-IL-4 prolonged IL-12 to 7 dpi along with reduced IL-10 in lungs. Overall, the immunoregulatory cytokines TGF-β and IL-4 dampen initial inflammation in this maSARS-CoV-2 infection, suggesting that promotion of immunoregulation could help patients in early stages of disease. Visual